Masimo Corporation reported its financial results for the third quarter of 2025, revealing a total revenue of $371.5 million, an increase of 8.2% from $343.3 million in the same period last year. The growth was primarily driven by higher capital equipment sales and other revenue streams, with a notable contribution of approximately $1.9 million from favorable foreign exchange rate movements. The company's gross profit for the quarter was $230.6 million, representing a gross margin of 62.1%, up from 61.8% in the prior year, attributed to operational efficiencies and product cost reductions despite facing $5.3 million in incremental tariffs.
In terms of profitability, Masimo reported an operating income of $83.6 million for the quarter, significantly higher than the $38.2 million recorded in the same quarter of 2024. However, the company experienced a net loss of $100.4 million, compared to a net income of $9.8 million in the prior year, largely due to a loss from discontinued operations amounting to $154.1 million. This loss was primarily related to the sale of its non-healthcare business, Sound United, which was completed on September 23, 2025, for approximately $350 million.
Operationally, Masimo's healthcare segment continues to show resilience, with revenues from direct and distribution sales channels increasing by 6.2% to $330.1 million. The company shipped approximately 66,000 noninvasive technology boards and instruments during the quarter, up from 60,500 in the previous year. The total employee headcount as of September 27, 2025, was not disclosed, but the company has been actively managing its workforce in response to market conditions and operational needs.
Strategically, Masimo has focused on enhancing its product offerings and expanding its market presence. The company has been investing in research and development, with expenses decreasing to $30.5 million from $37.3 million year-over-year, reflecting a shift in focus towards more efficient project management. The company also reported a significant reduction in selling, general, and administrative expenses, which fell to $116.4 million from $136.6 million, primarily due to lower legal and professional fees.
Looking ahead, Masimo remains optimistic about its long-term growth prospects despite the challenges posed by economic conditions, including inflation and supply chain volatility. The company anticipates that its existing cash reserves, along with available borrowing capacity under its credit facility, will be sufficient to support ongoing operations and capital expenditures for the next 12 months. The management is also closely monitoring the impacts of recent tax law changes and geopolitical developments on its business operations.
About MASIMO CORP
Masimo Corporation is a global leader in noninvasive patient monitoring technologies, offering advanced pulse oximetry, hemoglobin, and multi-parameter devices for hospitals, clinics, and home care. Its core products include sensors, monitors, and connectivity platforms that improve clinical outcomes and workflow efficiency. Serving healthcare providers worldwide, Masimo emphasizes innovation, interoperability, and patient-centered solutions to enhance care quality across diverse medical settings.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.